Advanced systemic mastocytosis is a rare diagnosis, yet treatment options are increasing with new FDA approvals. In this commentary, I review current treatments and the most clinically important studies on advanced systemic mastocytosis from ASH 2021.
Despite the rarity of systemic mastocytosis, multiple therapies are available to manage advanced disease. In this commentary, I review key data on current treatment options and how I individualize therapy for patients with advanced systemic mastocytosis.
Learn how the experts incorporate KIT-targeted therapies into management of patients with advanced systemic mastocytosis in this multidisciplinary panel discussion featuring Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky.
Get up to date on multidisciplinary care of patients with advanced systemic mastocytosis in this interactive text module featuring expert perspectives on diagnosis, classification, treatment selection, and management of toxicities associated with targeted therapies.
Review this slideset on the optimal management of advanced systemic mastocytosis using targeted agents.